rabeprazole sodium
CLINICAL USE
Gastric acid suppression
DOSE IN NORMAL RENAL FUNCTION
10–120 mg daily, doses >100 mg in 2 divided doses
PHARMACOKINETICS
Molecular weight                           :381.4 %Protein binding                           :97 %Excreted unchanged in urine     : 0 (90 as metabolites) Volume of distribution (L/kg)       :0.34half-life – normal/ESRD (hrs)      :0.7–1.5/Unchanged DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in normal renal function HD                     :Not dialysed. Dose as in normal renal functionHDF/high flux   :Unlikely to be dialysed. Dose as in normal renal functionCAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs Antifungals: absorption of itraconazole and ketoconazole reduced ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
Interstitial nephritis has been reported with rabeprazole sodium.
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home